Hospital
Falmouth Hospital Association INC
Falmouth Hospital Association INC was paid $25.40M by Medicaid between Jan 2018 and Dec 2024, across 244 billing codes. Its largest line is 99285, emergency room visit (most serious) — 15% of everything it billed.
33Billing provider infoFALMOUTH HOSPITAL ASSOCIATION INC
FALMOUTH, MA 02540
FALMOUTH, MA 02540
33aNPI1336106806assigned 04/28/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$25.40M
24GClaims614,307
24DCodes billed244
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Massachusetts
Rank by total paid#37 of 66
Median peer was paid$29.11M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 86,407 | $4.05M | |
| 2019 | 87,628 | $3.74M | |
| 2020 | 72,067 | $2.57M | |
| 2021 | 92,061 | $3.32M | |
| 2022 | 102,218 | $4.14M | |
| 2023 | 96,377 | $4.22M | |
| 2024incomplete | 77,549 | $3.36M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 24,972 | 22,075 | $3.90M |
| 96361 | Intravenous infusion, hydration; each additional hour | 13% | 8,945 | 7,832 | $3.19M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10.0% | 16,424 | 15,100 | $2.53M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.0% | 15,132 | 13,691 | $2.28M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5.2% | 19,005 | 5,938 | $1.31M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.1% | 7,734 | 6,573 | $787K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.7% | 13,372 | 11,630 | $685K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.6% | 5,676 | 5,226 | $669K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.6% | 4,312 | 4,046 | $652K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 2.0% | 2,787 | 1,249 | $516K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.4% | 4,692 | 4,595 | $348K |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 10,120 | 9,548 | $344K |
232 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 2,293 | $338K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.2% | 7,093 | $305K |
| 99213 | Doctor's office visit, returning patient (routine) | 1.1% | 1,663 | $275K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.1% | 2,195 | $273K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.1% | 2,260 | $268K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,178 | $244K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 8,691 | $240K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 881 | $226K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,646 | $222K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,177 | $207K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,502 | $206K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,509 | $199K |
| 76830 | Ultrasound, transvaginal | <1% | 2,110 | $196K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,230 | $187K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 214 | $185K |
| 93971 | <1% | 1,058 | $176K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 4,398 | $160K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 33,070 | $152K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,604 | $141K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 3,743 | $139K |
| 76642 | <1% | 1,575 | $137K | |
| J3490 | Unclassified drugs | <1% | 3,884 | $127K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,701 | $120K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 834 | $113K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,335 | $110K |
| S9485 | Crisis intervention mental health services, per diem | <1% | 221 | $109K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 670 | $87K |
| 73630 | <1% | 2,705 | $80K | |
| G0378 | Hospital observation service, per hour | <1% | 4,514 | $77K |
| 97162 | <1% | 1,286 | $74K | |
| 72100 | <1% | 2,422 | $73K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,662 | $73K |
| 76801 | <1% | 497 | $69K | |
| 73610 | <1% | 1,908 | $65K | |
| 73030 | <1% | 2,093 | $65K | |
| 76536 | <1% | 610 | $63K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 78 | $62K |
| ATP15 | <1% | 7,003 | $62K | |
| 77065 | Tomosynthesis, mammo | <1% | 877 | $61K |
| 73564 | <1% | 1,734 | $57K | |
| 84484 | <1% | 10,130 | $56K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 161 | $54K |
| 83735 | <1% | 13,164 | $52K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 835 | $52K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 64 | $49K |
| 73130 | <1% | 1,576 | $48K | |
| 97161 | <1% | 806 | $48K | |
| ATP08 | <1% | 6,920 | $48K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,613 | $47K |
| 62323 | <1% | 77 | $47K | |
| 71250 | <1% | 692 | $46K | |
| 93017 | <1% | 677 | $46K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 63 | $46K |
| 83690 | <1% | 10,366 | $45K | |
| ATP14 | <1% | 5,160 | $45K | |
| 93975 | <1% | 412 | $41K | |
| 83880 | <1% | 2,355 | $41K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,901 | $36K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 121 | $36K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 124 | $35K |
| 59025 | Fetal non-stress test | <1% | 150 | $35K |
| 83605 | <1% | 5,556 | $35K | |
| 73110 | <1% | 1,088 | $34K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 17,322 | $34K |
| 84703 | <1% | 5,829 | $33K | |
| 80053 | Comprehensive metabolic panel | <1% | 17,359 | $32K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 12,190 | $32K |
| 77080 | <1% | 617 | $31K | |
| 73502 | <1% | 1,107 | $31K | |
| 73221 | <1% | 95 | $29K | |
| 87430 | <1% | 2,291 | $27K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 844 | $27K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 20,092 | $27K |
| 77066 | Tomosynthesis, mammo | <1% | 380 | $26K |
| 87040 | <1% | 4,094 | $26K | |
| 94060 | <1% | 223 | $25K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,747 | $23K |
| 74018 | <1% | 509 | $21K | |
| 76770 | <1% | 142 | $20K | |
| 93970 | <1% | 58 | $20K | |
| 71045 | Radiologic examination, chest; single view | <1% | 10,795 | $20K |
| 71271 | <1% | 446 | $19K | |
| 85027 | <1% | 5,167 | $18K | |
| 87070 | <1% | 3,132 | $18K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 11,835 | $18K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,947 | $18K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 379 | $17K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 683 | $16K |
| 85610 | <1% | 7,502 | $16K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 673 | $16K |
| 87077 | <1% | 3,122 | $15K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,366 | $14K |
| 81003 | <1% | 10,081 | $14K | |
| 72141 | <1% | 97 | $13K | |
| 86317 | <1% | 755 | $13K | |
| 73560 | <1% | 233 | $13K | |
| 86850 | <1% | 2,218 | $13K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,721 | $12K |
| 81025 | <1% | 2,205 | $12K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,606 | $12K |
| 85730 | <1% | 3,316 | $12K | |
| 87186 | <1% | 2,347 | $12K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 237 | $12K |
| 43235 | <1% | 12 | $11K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,332 | $11K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 152 | $11K |
| 85379 | <1% | 1,754 | $10K | |
| 95811 | <1% | 12 | $10K | |
| J7999 | Compounded drug, not otherwise classified | <1% | 278 | $10K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 147 | $10K |
| 94726 | <1% | 245 | $10K | |
| 72050 | <1% | 176 | $10K | |
| 73140 | <1% | 239 | $10K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 55 | $9K |
| 73080 | <1% | 203 | $9K | |
| 86618 | <1% | 774 | $9K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 57 | $9K |
| 86140 | <1% | 2,929 | $9K | |
| 96367 | <1% | 529 | $8K | |
| 82948 | <1% | 2,847 | $8K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,585 | $8K |
| 81001 | <1% | 4,254 | $8K | |
| 94729 | <1% | 173 | $8K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 129 | $8K |
| 80076 | <1% | 6,897 | $7K | |
| 74019 | <1% | 1,007 | $7K | |
| 82803 | <1% | 582 | $7K | |
| 87081 | <1% | 1,197 | $7K | |
| 87476 | <1% | 314 | $7K | |
| 87088 | <1% | 1,368 | $6K | |
| 97035 | <1% | 126 | $6K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 28 | $5K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 100 | $5K |
| 82248 | <1% | 5,000 | $5K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,308 | $4K |
| 86900 | <1% | 2,272 | $4K | |
| 12001 | <1% | 13 | $4K | |
| 86901 | <1% | 2,268 | $4K | |
| 77002 | <1% | 55 | $4K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 26 | $3K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,453 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,519 | $3K |
| J2704 | Injection, propofol, 10 mg | <1% | 4,082 | $3K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 60 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,730 | $3K |
| 90715 | <1% | 112 | $3K | |
| 85652 | <1% | 1,697 | $3K | |
| 87632 | <1% | 17 | $2K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 997 | $2K |
| 84702 | <1% | 175 | $2K | |
| 87205 | <1% | 933 | $2K | |
| 73562 | <1% | 53 | $2K | |
| 84439 | <1% | 294 | $2K | |
| 85007 | <1% | 829 | $2K | |
| 97597 | <1% | 135 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,234 | $2K |
| 71101 | <1% | 106 | $2K | |
| 76813 | <1% | 14 | $1K | |
| 70496 | <1% | 12 | $1K | |
| 93880 | <1% | 26 | $1K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 17 | $1K |
| S0028 | Injection, famotidine, 20 mg | <1% | 19 | $1K |
| 81015 | <1% | 651 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,289 | $1K |
| 94664 | <1% | 22 | $926.94 | |
| 86880 | <1% | 321 | $888.32 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,827 | $809.23 |
| 82550 | <1% | 1,206 | $751.90 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 54 | $732.96 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,217 | $628.11 |
| 72040 | <1% | 12 | $605.76 | |
| ATP17 | <1% | 77 | $548.50 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,610 | $535.45 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 987 | $534.78 |
| 0011A | <1% | 74 | $508.20 | |
| 88342 | <1% | 54 | $507.17 | |
| 73700 | <1% | 32 | $486.73 | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 182 | $480.72 |
| 70486 | <1% | 13 | $476.54 | |
| 87210 | <1% | 113 | $428.16 | |
| 0012A | <1% | 22 | $397.46 | |
| 97116 | <1% | 18 | $395.02 | |
| 73590 | <1% | 15 | $323.33 | |
| 72070 | <1% | 12 | $319.79 | |
| ATP16 | <1% | 43 | $315.81 | |
| 87469 | <1% | 17 | $313.04 | |
| 87484 | <1% | 17 | $313.04 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,291 | $311.74 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,050 | $305.77 |
| 80061 | Lipid panel | <1% | 236 | $282.63 |
| 82150 | <1% | 71 | $280.56 | |
| 82140 | <1% | 46 | $274.25 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,591 | $269.37 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 369 | $264.18 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 798 | $258.74 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 521 | $228.17 |
| 96376 | <1% | 3,968 | $216.95 | |
| 87420 | <1% | 17 | $208.59 | |
| 90656 | <1% | 20 | $203.70 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 40 | $200.20 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 260 | $166.85 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 194 | $156.66 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 84 | $149.16 |
| 73090 | <1% | 13 | $107.78 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 841 | $103.76 |
| Q3014 | Telehealth originating site facility fee | <1% | 420 | $74.39 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 12 | $74.08 |
| 80178 | <1% | 13 | $47.74 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,460 | $23.94 |
| 82962 | <1% | 1,767 | $8.35 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 693 | $2.72 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 161 | $1.94 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 306 | $0.00 |
| 84100 | 0% | 365 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 390 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 274 | $0.00 |
| A4649 | Surgical supply; miscellaneous | 0% | 13 | $0.00 |
| 93356 | 0% | 47 | $0.00 | |
| 80179 | 0% | 54 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 71 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 21 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 1,285 | $0.00 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 73 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 124 | $0.00 |
| 94760 | 0% | 935 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 42 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 45 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 179 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 80 | $0.00 |
| 80320 | 0% | 52 | $0.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 15 | $0.00 |
| 91301 | 0% | 90 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDAYTON, REBECCA (VP OF REVENUE CYCLE)
| Provider | Location | Paid |
|---|---|---|
| Cape Cod Hospital INC | Hyannis, MA | $86.94M |
| Medical Affiliates of Cape Cod, INC. | Hyannis, MA | $5.91M |
| Urgi Center Medical Group | Sandwich, MA | $5.85M |
| Physicians of Cape Cod Hospital | Hyannis, MA | $5.21M |
| Emergency Physicians of Falmouth | Falmouth, MA | $2.69M |
| Physicians of Falmouth Hospital | Falmouth, MA | $346K |
| Cape Cod Hospital INC | Hyannis, MA | $291K |
| Radiologists of Cape Cod Hospital | Hyannis, MA | $51K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.